Tumor volume decrease at 8 weeks is associated with longer survival in EGFR-mutant advanced non-small-cell lung cancer patients treated with EGFR TKI.
about
Revisiting the relationship between tumour volume and diameter in advanced NSCLC patients: An exercise to maximize the utility of each measure to assess response to therapyResponse assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome.Depth of remission is a prognostic factor for survival in patients with metastatic renal cell carcinomaAccuracy and feasibility of estimated tumour volumetry in primary gastric gastrointestinal stromal tumours: validation using semiautomated technique in 127 patients.Volumetric Tumor Response and Progression in EGFR-mutant NSCLC Patients Treated with Erlotinib or GefitinibComparison of CT volumetric measurement with RECIST response in patients with lung cancer.Volumetric tumor growth in advanced non-small cell lung cancer patients with EGFR mutations during EGFR-tyrosine kinase inhibitor therapy: developing criteria to continue therapy beyond RECIST progressionMonitoring immune-checkpoint blockade: response evaluation and biomarker development.Pharmacometric Modeling of Liver Metastases' Diameter, Volume, and Density and Their Relation to Clinical Outcome in Imatinib-Treated Patients With Gastrointestinal Stromal Tumors.The prognostic value of CT radiomic features for patients with pulmonary adenocarcinoma treated with EGFR tyrosine kinase inhibitors.Immune-Related Tumor Response Dynamics in Melanoma Patients Treated with Pembrolizumab: Identifying Markers for Clinical Outcome and Treatment Decisions.Co-clinical quantitative tumor volume imaging in ALK-rearranged NSCLC treated with crizotinib.
P2860
Q33929944-7F41B671-060A-4E2C-A079-8589E612DF51Q34537285-95307548-7390-439F-88A2-574C62C1BCC9Q36062302-B6DCEC62-B1AF-4960-BD6F-D6764A92AFF3Q36303750-12FA6DA0-6942-485D-B939-ECC8B1BF247AQ36553854-531116FE-CD2A-4BBA-A379-90B0A7905C98Q36569753-07EDB2E2-D8BD-4B30-B6C8-94213A2C46A4Q37280018-B8BAAC7F-A18B-4F0A-A3B6-0DF094ADAB7DQ38666241-258F51E8-E073-4A02-A698-C3C6EA0143F2Q38852974-553ABF5B-E2A0-45AD-894F-0CDD96F84BB6Q45215365-7F4329FD-DDA2-4928-BD80-6216544A579CQ48771882-B6F38D53-D284-42EC-BCCD-36DBC5835738Q50898344-9D1C8DD9-712E-4056-BA99-5B6AB1303683
P2860
Tumor volume decrease at 8 weeks is associated with longer survival in EGFR-mutant advanced non-small-cell lung cancer patients treated with EGFR TKI.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Tumor volume decrease at 8 wee ...... atients treated with EGFR TKI.
@en
Tumor volume decrease at 8 wee ...... atients treated with EGFR TKI.
@nl
type
label
Tumor volume decrease at 8 wee ...... atients treated with EGFR TKI.
@en
Tumor volume decrease at 8 wee ...... atients treated with EGFR TKI.
@nl
prefLabel
Tumor volume decrease at 8 wee ...... atients treated with EGFR TKI.
@en
Tumor volume decrease at 8 wee ...... atients treated with EGFR TKI.
@nl
P2093
P2860
P1476
Tumor volume decrease at 8 wee ...... atients treated with EGFR TKI.
@en
P2093
Bruce E Johnson
David M Jackman
Hiroto Hatabu
Michael S Rabin
Mizuki Nishino
Stephanie Cardarella
Suzanne E Dahlberg
P2860
P304
P356
10.1097/JTO.0B013E318294C909
P50
P577
2013-08-01T00:00:00Z